Incyte Corporation $INCY Shares Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. grew its holdings in Incyte Corporation (NASDAQ:INCY) by 16.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 36,984 shares of the biopharmaceutical company’s stock after buying an additional 5,189 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Incyte were worth $4,556,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. BlackRock Inc. purchased a new position in Incyte in the 2nd quarter valued at approximately $2,044,189,000. Wellington Management Group LLP boosted its holdings in shares of Incyte by 9.5% in the second quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock worth $405,321,000 after acquiring an additional 309,385 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Incyte by 10.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock worth $185,873,000 after acquiring an additional 187,354 shares during the period. Pacer Advisors Inc. grew its position in shares of Incyte by 2.2% in the first quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock valued at $163,869,000 after purchasing an additional 37,790 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Incyte in the second quarter valued at $182,054,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Incyte Stock Down 0.1%

Shares of INCY stock opened at $116.80 on Friday. The business has a 50-day moving average price of $120.62 and a two-hundred day moving average price of $108.07. Incyte Corporation has a 12-month low of $89.25 and a 12-month high of $132.60. The firm has a market cap of $23.68 billion, a P/E ratio of 14.72, a price-to-earnings-growth ratio of 4.83 and a beta of 0.74.

Incyte (NASDAQ:INCY) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The company had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter in the previous year, the company posted $2.26 EPS. Incyte’s quarterly revenue was up 14.0% compared to the same quarter last year. As a group, research analysts expect that Incyte Corporation will post 1.97 EPS for the current fiscal year.

Insider Activity

In related news, insider Pablo Cagnoni sold 2,642 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $112.71, for a total transaction of $297,779.82. Following the transaction, the insider owned 183,200 shares of the company’s stock, valued at approximately $20,648,472. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 16.20% of the company’s stock.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $1.56 billion, exceeding the roughly $1.46 billion analyst estimate. The adjusted loss of $3.60 per share was also narrower than expected, reflecting solid underlying business performance. Incyte Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Incyte raised its 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance increased to $1.10 billion-$1.12 billion, supported by strong demand. Incyte Raises 2026 Sales Outlook
• Positive Sentiment: Key products performed well: Opzelura sales increased 36% to $255 million, Hematology and Oncology portfolio sales rose 38% to $235 million, and Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Third-Quarter Revenue and Guidance Update
• Positive Sentiment: Pipeline sentiment also improved after early data characterized Incyte’s G12D program as competitive in pancreatic cancer, while a partner began a Phase 1 study combining INCA33890 with another therapy in colorectal cancer. Incyte G12D Pipeline Update
• Neutral Sentiment: Management’s earnings call highlighted $3.9 billion in cash, cash equivalents and marketable securities at quarter-end, providing financial flexibility for development and acquisitions. Incyte Q3 Earnings Call Transcript
• Negative Sentiment: Incyte reported a GAAP net loss of approximately $785 million, or $3.86 per share, versus a profit in the prior-year quarter. The result was primarily driven by a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. Incyte Q3 Loss and Vega Acquisition Charge
• Negative Sentiment: Although guidance was raised, some investors viewed the new full-year sales range as below the level implied by consensus expectations, limiting the positive reaction to the earnings beat.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays increased their price objective on Incyte from $134.00 to $139.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Leerink Partners upped their price target on Incyte from $131.00 to $155.00 and gave the company an “outperform” rating in a research report on Monday, August 3rd. Benchmark reissued a “buy” rating on shares of Incyte in a report on Tuesday, October 13th. Zacks Research lowered shares of Incyte from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 14th. Finally, Royal Bank Of Canada boosted their price objective on shares of Incyte from $109.00 to $114.00 and gave the company a “sector perform” rating in a research note on Thursday, October 8th. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $131.43.

Incyte Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.